ArkBio has concluded enrolment and dosing for a Phase I trial of AK0610, to prevent RSV infection, particularly in vulnerable ...

Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

Cybersecurity is another critical issue, as health data is particularly vulnerable to breaches, which can lead to identity ...

The Global Coalition for Adaptive Research (GCAR) has executed an agreement to evaluate AstraZeneca's AZD1390 in the GBM ...

The biopharmaceutical industry is being called to take its sustainability efforts to the next level. A new report sheds light ...

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous HBV)-specific TCR-T therapy, ...